US FDA Approves First Injectable Intravenous Suspension for Contrast-Enhanced Liver Ultrasonography
By MedImaging International staff writers Posted on 11 Apr 2016 |
A leading global diagnostic imaging company has announced US FDA approval of injectable contrast agent for the characterization of focal liver lesions, using ultrasonography of the liver.
The US Food and Drug Administration (FDA; Silver Spring, MD USA) approved the contrast agent, “sulfur hexafluoride lipid-type A microspheres,” for use in adults with suboptimal echocardiograms, and also for children. This is the first ultrasound contrast agent approved by US FDA approval for use in liver imaging, and the first one approved for pediatric patients. The agent improves the sensitivity, and specificity of ultrasonography, and helps surgeons differentiate between focal hepatic lesions that are benign and those that are malignant.
The LUMASON agent, also called SonoVue, was developed by Bracco Imaging (Monroe Township, NJ, USA), and is already being used in Europe and Asia. The agent consists of gas-filled microspheres which reflect sound waves, and enhance the ultrasonographic images. The system has a proven safety, and efficacy profile for liver ultrasonography, and echocardiography, and is packaged in a three-part kit that does not need mechanical agitation, or refrigeration.
Alberto Spinazzi, MD, senior VP, global medical and regulatory affairs, in the Bracco group, said, “We are proud to be the first company to obtain FDA approval for this important clinical use of ultrasound contrast both in adults and children. This new indication for LUMASON reflects our efforts and investments to expand the range of approved clinical indications for contrast enhanced ultrasound in the United States. We are very pleased with the collaborative work with the FDA whose review is critical to ensuring the safety and efficacy of any use of imaging products to the healthcare community.”
Related Links:
FDA
Bracco
The US Food and Drug Administration (FDA; Silver Spring, MD USA) approved the contrast agent, “sulfur hexafluoride lipid-type A microspheres,” for use in adults with suboptimal echocardiograms, and also for children. This is the first ultrasound contrast agent approved by US FDA approval for use in liver imaging, and the first one approved for pediatric patients. The agent improves the sensitivity, and specificity of ultrasonography, and helps surgeons differentiate between focal hepatic lesions that are benign and those that are malignant.
The LUMASON agent, also called SonoVue, was developed by Bracco Imaging (Monroe Township, NJ, USA), and is already being used in Europe and Asia. The agent consists of gas-filled microspheres which reflect sound waves, and enhance the ultrasonographic images. The system has a proven safety, and efficacy profile for liver ultrasonography, and echocardiography, and is packaged in a three-part kit that does not need mechanical agitation, or refrigeration.
Alberto Spinazzi, MD, senior VP, global medical and regulatory affairs, in the Bracco group, said, “We are proud to be the first company to obtain FDA approval for this important clinical use of ultrasound contrast both in adults and children. This new indication for LUMASON reflects our efforts and investments to expand the range of approved clinical indications for contrast enhanced ultrasound in the United States. We are very pleased with the collaborative work with the FDA whose review is critical to ensuring the safety and efficacy of any use of imaging products to the healthcare community.”
Related Links:
FDA
Bracco
Latest Ultrasound News
- Diagnostic System Automatically Analyzes TTE Images to Identify Congenital Heart Disease
- Super-Resolution Imaging Technique Could Improve Evaluation of Cardiac Conditions
- First AI-Powered POC Ultrasound Diagnostic Solution Helps Prioritize Cases Based On Severity
- Largest Model Trained On Echocardiography Images Assesses Heart Structure and Function
- Groundbreaking Technology Enables Precise, Automatic Measurement of Peripheral Blood Vessels
- Deep Learning Advances Super-Resolution Ultrasound Imaging
- Novel Ultrasound-Launched Targeted Nanoparticle Eliminates Biofilm and Bacterial Infection
- AI-Guided Ultrasound System Enables Rapid Assessments of DVT
- Focused Ultrasound Technique Gets Quality Assurance Protocol
- AI-Guided Handheld Ultrasound System Helps Capture Diagnostic-Quality Cardiac Images
- Non-Invasive Ultrasound Imaging Device Diagnoses Risk of Chronic Kidney Disease
- Wearable Ultrasound Platform Paves Way for 24/7 Blood Pressure Monitoring On the Wrist
- Diagnostic Ultrasound Enhancing Agent to Improve Image Quality in Pediatric Heart Patients
- AI Detects COVID-19 in Lung Ultrasound Images
- New Ultrasound Technology to Revolutionize Respiratory Disease Diagnoses
- Dynamic Contrast-Enhanced Ultrasound Highly Useful For Interventions